MGX-001 development timeline and preclinical update
Metagenomi Therapeutics targeted a 4Q 2026 IND filing for MGX-001 in hemophilia A, setting up a potential first-in-human study in 2027.
Non-human primate preclinical findings supporting MGX-001 were already presented in scientific posters that won top awards at the 2026 ISTH Congress.
IND-enabling work is expected to finish by end-3Q 2026, positioning the program for a global clinical rollout pending regulatory clearance.
Cash, cash equivalents, and available-for-sale marketable securities totaled USD 120.7 million at June 30, 2026, with runway projected through 4Q 2027.
MGX•
